Last reviewed · How we verify
Cannabidiol 200mg
Cannabidiol 200mg is a Small molecule drug developed by Yasmin Hurd. It is currently in Phase 1 development. Also known as: BSPG CBD.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Cannabidiol 200mg |
|---|---|
| Also known as | BSPG CBD |
| Sponsor | Yasmin Hurd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Drowsiness
- Headache
- Nausea
- Appetite Increase
- Dizziness
- Fatigue
- Photosensitivity
- Chills
- Tachycardia
- Abdominal Cramp
- Appetite Decrease
- Dry Mouth
Key clinical trials
- Cannabidiol and Alcohol Use Disorder Phenotypes (PHASE2)
- Cannabidiol as a Treatment for Social Anxiety Disorder (R61) (PHASE2)
- Adjunctive Cannabidiol for Recovery From Opioid Study (PHASE3)
- Cannabis for Palliative Care in Cancer (PHASE2)
- Relative Bioavailability of Two Orally Administered CBD Formulations in Healthy Male Adults (PHASE1)
- Investigation of the Pharmacokinetic Profile of CBD (PHASE1)
- Cannabidiol in the Treatment of Opioid Use Disorder (PHASE2)
- Cannabidiol Effects on Blood Alcohol Level and Intoxication (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cannabidiol 200mg CI brief — competitive landscape report
- Cannabidiol 200mg updates RSS · CI watch RSS
- Yasmin Hurd portfolio CI
Frequently asked questions about Cannabidiol 200mg
What is Cannabidiol 200mg?
Who makes Cannabidiol 200mg?
Is Cannabidiol 200mg also known as anything else?
What development phase is Cannabidiol 200mg in?
What are the side effects of Cannabidiol 200mg?
Related
- Manufacturer: Yasmin Hurd — full pipeline
- Also known as: BSPG CBD
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing